Perioperative Complications Not Deciding Factor Between Two Bariatric Procedures
For patients undergoing primary bariatric surgery, perioperative complications and safety were similar between laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass (RYGB), the randomized BEST trial found. Incidence of any adverse event (AE) at 30 days didn’t significantly differ, occurring in 4.6% of sleeve gastrectomy and 6.3% of RYGB patients (OR 0.71, 95% CI 0.47-1.08, […]
New Data in NSCLC Bolster Support for Perioperative Immunotherapy
CHICAGO — A randomized trial testing the addition of perioperative pembrolizumab (Keytruda) to chemotherapy in operable non-small cell lung cancer (NSCLC) hit one of its two primary endpoints in an interim analysis, with a favorable trend for the other. All patients in the study received cisplatin-based neoadjuvant chemotherapy, and at 2 years, the event-free survival […]
Upfront Systemic Therapy, Deferred Surgery Pass Muster in Advanced Kidney Cancer
CHICAGO — Perioperative immunotherapy for advanced kidney cancer did not adversely affect outcomes with cytoreductive nephrectomy and appeared to have several beneficial effects, a small multicenter study showed. Primary immunotherapy significantly reduced median tumor size and thrombus length and improved tumor thrombus level and mean RENAL score. Immunotherapy led to pathologic downstaging in 25 of […]
Perioperative Toripalimab Prolongs EFS in Stage III Lung Cancer
Adding an investigational anti-PD-1 drug to perioperative chemotherapy improved event-free survival (EFS) in patients with resectable, stage III non-small cell lung cancer (NSCLC), an interim analysis of a phase III study found. Among 404 patients receiving perioperative chemotherapy in the so-called Neotorch trial, the median investigator-assessed EFS was not reached in patients assigned to toripalimab, […]